Zacks Research Issues Optimistic Forecast for PAHC Earnings

Phibro Animal Health Co. (NASDAQ:PAHC) – Investment analysts at Zacks Research increased their Q1 2027 earnings per share (EPS) estimates for shares of Phibro Animal Health in a report issued on Tuesday, January 7th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.49 for the quarter, up from their previous forecast of $0.47. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.62 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q2 2027 earnings at $0.53 EPS.

A number of other research analysts have also recently commented on the company. Morgan Stanley raised their price target on Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Barclays raised their price target on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Finally, StockNews.com upgraded Phibro Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 4th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Phibro Animal Health presently has an average rating of “Hold” and a consensus price target of $20.50.

Phibro Animal Health Stock Up 3.9 %

PAHC stock opened at $21.48 on Friday. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69. The stock has a market capitalization of $870.00 million, a price-to-earnings ratio of 49.95, a PEG ratio of 0.58 and a beta of 0.53. The business’s fifty day moving average price is $22.81 and its two-hundred day moving average price is $21.06. Phibro Animal Health has a fifty-two week low of $10.03 and a fifty-two week high of $25.98.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PAHC. Sofinnova Investments Inc. acquired a new stake in shares of Phibro Animal Health during the second quarter valued at about $3,975,000. American Century Companies Inc. boosted its stake in shares of Phibro Animal Health by 119.6% during the second quarter. American Century Companies Inc. now owns 347,191 shares of the company’s stock valued at $5,822,000 after purchasing an additional 189,068 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of Phibro Animal Health by 116.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company’s stock valued at $4,330,000 after purchasing an additional 103,491 shares in the last quarter. Dana Investment Advisors Inc. boosted its stake in shares of Phibro Animal Health by 17.2% during the second quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after purchasing an additional 75,546 shares in the last quarter. Finally, Algert Global LLC boosted its stake in shares of Phibro Animal Health by 521.1% during the third quarter. Algert Global LLC now owns 71,335 shares of the company’s stock valued at $1,606,000 after purchasing an additional 59,850 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th were given a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 2.23%. The ex-dividend date of this dividend was Wednesday, November 27th. Phibro Animal Health’s dividend payout ratio is presently 111.63%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.